Regulus recently published some very intriguing data with miR-21 in cancer and fibrosis models (the subject of their earlier deal with Sanofi), as well as miR-33 in lipid biology.
To better understand the relative attractiveness of the IPO market, and how their venture backers have done so far, I thought it would be illustrative to look at the biotech IPOs that have made it public since early July in greater depth: Durata, Hyperion, Regulus, Kythera, and Intercept.